Literature DB >> 25712044

Neurological heterotopic ossification following spinal cord injury is triggered by macrophage-mediated inflammation in muscle.

François Genêt1,2,3, Irina Kulina1,4, Cedryck Vaquette5, Frédéric Torossian6,7, Susan Millard1, Allison R Pettit1, Natalie A Sims8, Adrienne Anginot6,7, Bernadette Guerton6,7, Ingrid G Winkler1, Valérie Barbier1, Jean-Jacques Lataillade6,9, Marie-Caroline Le Bousse-Kerdilès6,7, Dietmar W Hutmacher1, Jean-Pierre Levesque1,4.   

Abstract

Neurological heterotopic ossification (NHO) is the abnormal formation of bone in soft tissues as a consequence of spinal cord or traumatic brain injury. NHO causes pain, ankyloses, vascular and nerve compression and delays rehabilitation in this high-morbidity patient group. The pathological mechanisms leading to NHO remain unknown and consequently there are no therapeutic options to prevent or reduce NHO. Genetically modified mouse models of rare genetic forms of heterotopic ossification (HO) exist, but their relevance to NHO is questionable. Consequently, we developed the first model of spinal cord injury (SCI)-induced NHO in genetically unmodified mice. Formation of NHO, measured by micro-computed tomography, required the combination of both SCI and localized muscular inflammation. Our NHO model faithfully reproduced many clinical features of NHO in SCI patients and both human and mouse NHO tissues contained macrophages. Muscle-derived mesenchymal progenitors underwent osteoblast differentiation in vitro in response to serum from NHO mice without additional exogenous osteogenic stimuli. Substance P was identified as a candidate NHO systemic neuropeptide, as it was significantly elevated in the serum of NHO patients. However, antagonism of substance P receptor in our NHO model only modestly reduced the volume of NHO. In contrast, ablation of phagocytic macrophages with clodronate-loaded liposomes reduced the size of NHO by 90%, supporting the conclusion that NHO is highly dependent on inflammation and phagocytic macrophages in soft tissues. Overall, we have developed the first clinically relevant model of NHO and demonstrated that a combined insult of neurological injury and soft tissue inflammation drives NHO pathophysiology.
Copyright © 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  heterotopic ossification; inflammation; macrophage; spinal cord injury

Mesh:

Substances:

Year:  2015        PMID: 25712044     DOI: 10.1002/path.4519

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  43 in total

Review 1.  Stem cells and heterotopic ossification: Lessons from animal models.

Authors:  John B Lees-Shepard; David J Goldhamer
Journal:  Bone       Date:  2018-01-31       Impact factor: 4.398

2.  Characterizing the Circulating Cell Populations in Traumatic Heterotopic Ossification.

Authors:  Shawn J Loder; Shailesh Agarwal; Michael T Chung; David Cholok; Charles Hwang; Noelle Visser; Kaetlin Vasquez; Michael Sorkin; Joe Habbouche; Hsiao H Sung; Joshua Peterson; David Fireman; Kavitha Ranganathan; Christopher Breuler; Caitlin Priest; John Li; Xue Bai; Shuli Li; Paul S Cederna; Benjamin Levi
Journal:  Am J Pathol       Date:  2018-08-22       Impact factor: 4.307

Review 3.  Arterial Calcification in Diabetes Mellitus: Preclinical Models and Translational Implications.

Authors:  John N Stabley; Dwight A Towler
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-12-22       Impact factor: 8.311

Review 4.  Heterotopic Ossification Following Upper Extremity Injury.

Authors:  Shailesh Agarwal; Shawn Loder; Benjamin Levi
Journal:  Hand Clin       Date:  2017-05       Impact factor: 1.907

5.  Crosstalk between substance P and calcitonin gene-related peptide during heterotopic ossification in murine Achilles tendon.

Authors:  Ceren Tuzmen; Kostas Verdelis; Lee Weiss; Phil Campbell
Journal:  J Orthop Res       Date:  2018-01-05       Impact factor: 3.494

6.  Effectiveness and mode of action of a combination therapy for heterotopic ossification with a retinoid agonist and an anti-inflammatory agent.

Authors:  Sayantani Sinha; Kenta Uchibe; Yu Usami; Maurizio Pacifici; Masahiro Iwamoto
Journal:  Bone       Date:  2016-02-15       Impact factor: 4.398

Review 7.  Cell death, clearance and immunity in the skeletal muscle.

Authors:  C Sciorati; E Rigamonti; A A Manfredi; P Rovere-Querini
Journal:  Cell Death Differ       Date:  2016-02-12       Impact factor: 15.828

Review 8.  Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification.

Authors:  Koji Matsuo; Robert Dalton Chavez; Emilie Barruet; Edward C Hsiao
Journal:  Curr Osteoporos Rep       Date:  2019-12       Impact factor: 5.096

9.  Macrophage-derived oncostatin M contributes to human and mouse neurogenic heterotopic ossifications.

Authors:  Frédéric Torossian; Bernadette Guerton; Adrienne Anginot; Kylie A Alexander; Christophe Desterke; Sabrina Soave; Hsu-Wen Tseng; Nassim Arouche; Laetitia Boutin; Irina Kulina; Marjorie Salga; Beulah Jose; Allison R Pettit; Denis Clay; Nathalie Rochet; Erica Vlachos; Guillaume Genet; Charlotte Debaud; Philippe Denormandie; François Genet; Natalie A Sims; Sébastien Banzet; Jean-Pierre Levesque; Jean-Jacques Lataillade; Marie-Caroline Le Bousse-Kerdilès
Journal:  JCI Insight       Date:  2017-11-02

Review 10.  The progress of early growth response factor 1 and leukemia.

Authors:  Jing Tian; Ziwei Li; Yang Han; Tao Jiang; Xiaoming Song; Guosheng Jiang
Journal:  Intractable Rare Dis Res       Date:  2016-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.